ChiCTR-IPR-15005758
正在进行
/
/
/
2015-01-02
/
/
comorbid generalized anxiety disorder and diarrhea-predominant irritable bowel syndrome
電針灸對同時患有經常焦慮症和肚瀉型腸易激綜合症的療效研究
電針灸對同時患有經常焦慮症和肚瀉型腸易激綜合症的療效研究
電針灸對同時患有經常焦慮症和肚瀉型腸易激綜合症的療效
随机平行对照
治疗新技术
block randomisation
Randomized
Health and Medical Research Fund
/
0;74
/
2015-01-15
1990-01-01
/
1. Rome III criteria for irritable bowel syndrome- diarrheal subtype: (1) Current (weekly) symptoms of type and severity: i. Abdominal pain intensity: weekly average of worst daily (in the past 24 hours) abdominal pain score of at least 1 on 0-4 5-point Likert scale, AND ii. Stool consistency: at least one stool with a consistency of Type 6 or Type 7 Bristol Stool Score in at least 25% of the time. (2) Normal colonic evaluation (colonoscopy or barium enema) within the past 5 years. 2. DSM-5 Criteria for Generalized Anxiety Disorder with GAD7 score 10 or above; 3. Age >18; 4. Provision of written consent.;
请登录查看1. Functional dyspepsia (Rome III definition) and/or Gastro-esophageal reflux disease (Montreal definition) as dominant syndrome; 2. Previous gastrointestinal surgery (except appendicectomy and cholecystectomy); 3. History of organic disease of the gastrointestinal tract, such as colorectal cancer, advanced colonic polyp, celiac disease, inflammatory bowel disease, previous gastrointestinal surgery or systemic diseases that may cause diarrhea; 4. Pregnancy, lactation or not under proper contraception; 5. Concomitant use of anti-diarrheal drugs; 6. History of drug abuse or regular alcohol use in recent 6 months; 7. Active suicidal thoughts or history of violence or suicide attempts; 8. Currently suffering from depression of at least moderate severity (PHQ-9 15 or above); 9. History of severe mental illness, such as psychosis, bipolar disorder, or organic brain syndrome that may limit the response of anxiety and somatic symptoms to electroacupuncture. 10. History of psychotropic drug use or treatment in recent month xi) Currently receiving psychological treatment.;
请登录查看Department of Medicine and Therapeutics,The Chinese University of Hong Kong
/
Department of Medicine and Therapeutics,The Chinese University of Hong Kong的其他临床试验
Department of Medicine and Therapeutics,The Chinese University of Hong Kong的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示:#脐带间充质干细胞(#hUC-MSCs)
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点,索弗度肽(survodutide)成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 60
-
摩熵咨询 20 3
-
颁布机构:国家卫生健康委办公厅、 2026-11-10
-
颁布机构:国家卫健委(原国家卫计委) 2026-11-10
-
颁布机构:国家药品审评中心(CDE) 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构:国家市场监督管理总局 2026-11-07
-
颁布机构:国家市场监督管理总局 2026-11-07
-
颁布机构:国家市场监督管理总局 2026-11-04

